Stocks · News reference
The FDA fully approves Eli Lilly's Inluriyo and Verzenio combination for advanced breast cancer, doubling progression-free survival.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
AstraZeneca closed at $168.10, up 1.22% but lagging the S&P 500's 1.49% gain. The stock has risen only 0.06% over the past month while underperforming its sector. Upcoming earnings are expected to show EPS of $2.17 (down 8.82% YoY) with revenue of $16.07 billion (up 5.82% YoY). The company received a Zacks Rank of #5 (Strong Sell) following an 8.49% decline in consensus EPS estimates over the past month.
William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radiopharmaceutical platform.
On Monday, AstraZeneca (NASDAQ:AZN) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial data
The article compares two dividend investment strategies: Eli Lilly offers modest 0.6% yield but exceptional 15.3% annual dividend growth rate and strong growth prospects in the GLP-1 market, while Pfizer provides a high 6.2% yield with sustainable dividends backed by $11 billion in free cash flow. The choice depends on investor priorities—Eli Lilly suits those seeking growth and future dividend increases, while Pfizer appeals to investors prioritizing immediate income.
TD Cowen analyst Steve Scala reiterates Eli Lilly (NYSE:LLY) with a Buy and maintains $1250 price target.
Public Citizen exposes separate government drug deals with Pfizer and Eli Lilly, warning the pacts could increase global drug prices.